- Home
- PKBK vs CNTX Comparison
PKBK vs CNTX Comparison
Compare PKBK & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PKBK | CNTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.7M | 283.9M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PKBK | CNTX |
|---|---|---|
| Price | $28.28 | $2.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 63.5K | ★ 947.7K |
| Earning Date | 04-16-2026 | 03-23-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 39.21 | 17.39 |
| EPS | ★ 3.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.94 | $0.49 |
| 52 Week High | $29.50 | $3.62 |
Technical Indicators
Market Signals| Indicator | PKBK | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.27 | 43.95 |
| Support Level | $26.56 | $2.07 |
| Resistance Level | $29.42 | $2.72 |
| Average True Range (ATR) | 0.64 | 0.30 |
| MACD | 0.09 | -0.09 |
| Stochastic Oscillator | 68.49 | 0.69 |
Price Performance
Historical ComparisonAbout PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.